| Phase 3 |
| NCT03828227 |
QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric… |
Elderly Patients |
Active, Not Recruiting |
| Phase 2 |
| NCT06059495 |
Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR… |
Adenocarcinoma - GEJ |
Recruiting |
| NCT05310643 |
Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC |
Metastatic Colorectal Cancer |
Recruiting |
| NCT04268121 |
Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive… |
Neuroendocrine Carcinoma |
Recruiting |
| NCT06253611 |
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer |
Gastric Cancer |
Recruiting |
| NCT04730544 |
Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and… |
Colorectal Cancer Metastatic |
Active, Not Recruiting |
| NCT06646445 |
Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon… |
Colon Cancer |
Not Yet Recruiting |
| NCT04006262 |
Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for… |
Localized Oesogastric Adenocarcimona |
Active, Not Recruiting |
| NCT07028424 |
PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line… |
PDAC - Pancreatic Ductal Adenocarcinoma |
Not Yet Recruiting |
| NCT07071844 |
BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in… |
Metastatic Colorectal Cancer |
Not Yet Recruiting |
| NCT03350126 |
iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients… |
Metastatic Cancer Colorectal |
Active, Not Recruiting |
| NCT03704480 |
Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. |
Advanced Biliary Tract Carcinoma |
Active, Not Recruiting |
| NCT03806309 |
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in… |
Pancreatic Ductal Adenocarcinoma |
Active, Not Recruiting |
| NCT04348045 |
Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and… |
Metastatic Pancreatic Adenocarcinoma |
Active, Not Recruiting |
| NCT04166604 |
LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy |
Metastatic Colorectal Cancer |
Active, Not Recruiting |
| Not specified |
| NCT05776342 |
Prognostic and Predictive Markers of Treatment Response in Patients With PAC. |
Pancreatic Adenocarcinoma |
Recruiting |
| NCT04935853 |
Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct… |
Biliary Tract Cancer |
Recruiting |
| NCT05787197 |
ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases |
Metastatic Colorectal Cancer |
Recruiting |
| NCT05850130 |
Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer… |
Colorectal Cancer |
Recruiting |
| NCT02979483 |
Management of Symptomatic Advanced Pancreatic Adenocarcinoma |
Pancreas |
Active, Not Recruiting |
| NCT06275737 |
POP-UP: a Single-arm, Two-cohort Study: an 8-week Trimodal Pre-habilitation Program for… |
Pancreatic Ductal Adenocarcinoma |
Active, Not Recruiting |